JACKSONVILLE, Fla. -- (BUSINESS WIRE) -- NovaBone Products, a leading developer of orthopedic and dental biomaterials, has begun relocation into a 30,000 square feet building in Alachua, Florida that will more than double the existing footprint of current facilities.
Arthur Wotiz, CEO NovaBone Products. (Photo: Business Wire)
The relocation provides significantly more manufacturing space to support the greater than 40% sales growth the company has experienced for each of the past four years. Moreover, the relocation combines the company’s manufacturing and research & development operations under one roof, greatly improving the process of new product development and introduction. The move to the new facility has started and is expected to be completed by year end.
While NovaBone Products has continued conducting a vigorous new product development program for bone graft products that meet desired performance and handling characteristics, there has been a greater emphasis on collagen products and collagen composite products.
"We are particularly excited over the progress we have made in developing a core competency with collagen,” said Arthur Wotiz, CEO of NovaBone Products. “We are well positioned to serve the orthopedic surgery, neurosurgery, plastic/reconstructive surgery, and the dental surgery industries with a variety of collagen based products along with our core bioactive technology.”
NovaBone Products was established in 2002 with a focus on developing bone graft substitutes based on advancements in biomedical engineering that would meet the specialized needs of orthopedic and dental surgeons.
Since its inception, the company has developed numerous formulations and delivery systems of its patented, bioactive technology platform that results in accelerated bone growth. In total, NovaBone's exclusively formulated bone graft substitute has been used for the repair of osseous defects throughout the skeletal system for over a decade and used in over a million clinical applications with unparalleled success validating the safety and efficacy of NovaBone’s technology.
NovaBone was the first bioactive synthetic bone graft offered to the orthopedic community; the unique properties of the product formulation gave rise to the need to scientifically define its bone-forming process, and in 2005, the FDA authorized the term “osteostimulation,” as a way to describe how our products signal genetic pathways to accelerate natural regeneration of bone.
Headquartered in Jacksonville, Florida, NovaBone Products includes operations in Alachua, Florida, as well as, Shanghai, PRC, and Bangalore, India.